COMPARISON
Teduglutide vs Vosoritide
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Teduglutide is authorised or registered in 7 and Vosoritide in 7 of the 10 registers read. Teduglutide: highest phase Phase 4 (after approval). Vosoritide: highest phase Phase 3 (3 phase 3 trials, 0 with posted results). 0 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Teduglutide | Vosoritide | |
|---|---|---|
| Registered trials differs | 51 clinicaltrials.gov · 2026-10-03 | 23 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: Gattex openfda · 2026-10-03T17:23:44.062Z | FDA-approved: VOXZOGO 0.4mg openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-10-03 |
| EU authorised on differs | 2012-08-30 ema · 2026-10-03 | 2021-08-26 ema · 2026-10-03 |
| ATC code differs | A16AX08 ema · 2026-10-03 | M05BX ema · 2026-10-03 |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Teduglutide | placebo | Vosoritide | placebo |
|---|---|---|---|---|
| Abdominal pain | 31.0% | 23.3% | - | - |
| Nausea | 28.6% | 18.6% | - | - |
| Gastrointestinal stoma complication | 23.8% | 7.0% | - | - |
| Abdominal distension | 21.4% | 2.3% | - | - |
| Central line systemic infections | 16.7% | 16.3% | - | - |
| Edema peripheral | 16.7% | 4.7% | - | - |
| Urinary tract infection | 14.3% | 9.3% | - | - |
| Flatulence | 11.9% | 7.0% | - | - |
| Vomiting | 11.9% | 9.3% | - | - |
| Catheter-related infection | 11.9% | 2.3% | - | - |
| Injection site reaction | - | - | 79.1% | 40.6% |
| Injection site erythema | - | - | 76.7% | 40.6% |
| Viral infection | - | - | 18.6% | 12.5% |
| Injection site swelling | - | - | 18.6% | 6.3% |
| Fall | - | - | 16.3% | 9.4% |
| Injection site urticaria | - | - | 14.0% | 3.1% |
| Arthropod bite | - | - | 14.0% | 6.3% |
| Injection site induration | - | - | 11.6% | 0.0% |
| Constipation | - | - | 11.6% | 6.3% |
| Rhinitis | - | - | 9.3% | 0.0% |
Trial register Teduglutide: 1 placebo-controlled trials; Vosoritide: 1. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Teduglutide side effects · Vosoritide side effects
LEGAL STATUS
Approval in each country read
| Country | Teduglutide | Vosoritide | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Not on the register | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Not on the register | Not on the register | Regulator ALIMS |
| Singapore | Not on the register | Not on the register | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.